1
|
den Uil SH, van den Broek E, Coupé VMH, Vellinga TT, Delis-van Diemen PM, Bril H, Belt EJT, Kranenburg O, Stockmann HBAC, Belien JAM, Meijer GA, Fijneman RJA. Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study. BMC Gastroenterol 2019; 19:146. [PMID: 31420015 PMCID: PMC6698008 DOI: 10.1186/s12876-019-1063-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Accepted: 07/31/2019] [Indexed: 01/01/2023] Open
Abstract
Background Microvessel density (MVD), as a derived marker for angiogenesis, has been associated with poor outcome in several types of cancer. This study aimed to evaluate the prognostic value of MVD in stage II and III colon cancer and its relation to tumour-stroma-percentage (TSP) and expression of HIF1A and VEGFA. Methods Formalin-fixed paraffin-embedded (FFPE) colon cancer tissues were collected from 53 stage II and 54 (5-fluorouracil-treated) stage III patients. MVD was scored by digital morphometric analysis of CD31-stained whole tumour sections. TSP was scored using haematoxylin-eosin stained slides. Protein expression of HIF1A and VEGFA was determined by immunohistochemical evaluation of tissue microarrays. Results Median MVD was higher in stage III compared to stage II colon cancers (11.1% versus 5.6% CD31-positive tissue area, p < 0.001). High MVD in stage II patients tended to be associated with poor disease free survival (DFS) in univariate analysis (p = 0.056). In contrast, high MVD in 5FU-treated stage III patients was associated with better DFS (p = 0.006). Prognostic value for MVD was observed in multivariate analyses for both cancer stages. Conclusions MVD is an independent prognostic factor associated with poor DFS in stage II colon cancer patients, and with better DFS in stage III colon cancer patients treated with adjuvant chemotherapy. Electronic supplementary material The online version of this article (10.1186/s12876-019-1063-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Sjoerd H den Uil
- Department of Surgery, Spaarne Gasthuis, Boerhaavelaan 22, Haarlem, 2035 RC, The Netherlands.,Department of Pathology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands
| | - Evert van den Broek
- Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, 9700 RB, The Netherlands.,Department of Pathology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands
| | - Veerle M H Coupé
- Department of Epidemiology and Biostatistics, VU University Medical Center, de Boelelaan 1089a, Amsterdam, 1081 HV, The Netherlands
| | - Thomas T Vellinga
- Department of Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands
| | - Pien M Delis-van Diemen
- Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands
| | - Herman Bril
- Department of Pathology, Spaarne Gasthuis, Boerhaavelaan 22, Haarlem, 2035 RC, The Netherlands
| | - Eric J Th Belt
- Department of Surgery, Albert Schweitzer Ziekenhuis, Dordrecht, 3300 AK, The Netherlands
| | - Onno Kranenburg
- Department of Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands
| | - Hein B A C Stockmann
- Department of Surgery, Spaarne Gasthuis, Boerhaavelaan 22, Haarlem, 2035 RC, The Netherlands
| | - Jeroen A M Belien
- Department of Pathology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands
| | - Gerrit A Meijer
- Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands
| | - Remond J A Fijneman
- Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
| |
Collapse
|
2
|
Borovski T, Vellinga TT, Laoukili J, Santo EE, Fatrai S, van Schelven S, Verheem A, Marvin DL, Ubink I, Borel Rinkes IHM, Kranenburg O. Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer. Gut 2017; 66:1106-1115. [PMID: 27670374 DOI: 10.1136/gutjnl-2016-311547] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Accepted: 08/30/2016] [Indexed: 12/08/2022]
Abstract
BACKGROUND AND AIM Colorectal cancer (CRC) remains one of the leading causes of cancer-related death. Novel therapeutics are urgently needed, especially for tumours with activating mutations in KRAS (∼40%). Here we investigated the role of RAF1 in CRC, as a potential, novel target. METHODS Colonosphere cultures were established from human tumour specimens obtained from patients who underwent colon or liver resection for primary or metastatic adenocarcinoma. The role of RAF1 was tested by generating knockdowns (KDs) using three independent shRNA constructs or by using RAF1-kinase inhibitor GW5074. Clone-initiating and tumour-initiating capacities were assessed by single-cell cloning and injecting CRC cells into immune-deficient mice. Expression of tight junction (TJ) proteins, localisation of polarity proteins and activation of MEK-ERK pathway was analysed by western blot, immunohistochemistry and immunofluorescence. RESULTS KD or pharmacological inhibition of RAF1 significantly decreased clone-forming and tumour-forming capacity of all CRC cultures tested, including KRAS-mutants. This was not due to cytotoxicity but, at least in part, to differentiation of tumour cells into goblet-like cells. Inhibition of RAF1-kinase activity restored apicobasal polarity and the formation of TJs in vitro and in vivo, without reducing MEK-ERK phosphorylation. MEK-inhibition failed to restore polarity and TJs. Moreover, RAF1-impaired tumours were characterised by normalised tissue architecture. CONCLUSIONS RAF1 plays a critical role in maintaining the transformed phenotype of CRC cells, including those with mutated KRAS. The effects of RAF1 are kinase-dependent, but MEK-independent. Despite the lack of activating mutations in RAF1, its kinase domain is an attractive therapeutic target for CRC.
Collapse
Affiliation(s)
- Tijana Borovski
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Thomas T Vellinga
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Jamila Laoukili
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Evan E Santo
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York City, New York, USA
| | - Szabolcs Fatrai
- Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
| | | | - Andre Verheem
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Dieuwke L Marvin
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Inge Ubink
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | - Onno Kranenburg
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
3
|
Ubink I, Jongen JMJ, Nijkamp MW, Meijer EFJ, Vellinga TT, van Hillegersberg R, Molenaar IQ, Borel Rinkes IHM, Hagendoorn J. Surgical and Oncologic Outcomes After Major Liver Surgery and Extended Hemihepatectomy for Colorectal Liver Metastases. Clin Colorectal Cancer 2016; 15:e193-e198. [PMID: 27297446 DOI: 10.1016/j.clcc.2016.04.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Revised: 03/23/2016] [Accepted: 04/27/2016] [Indexed: 02/09/2023]
Abstract
PURPOSE To determine the surgical and oncologic outcomes after major liver surgery for colorectal liver metastases (CRLM) at a Dutch University Hospital. PATIENTS AND METHODS Consecutive patients with CRLM who had undergone major liver resection, defined as ≥ 4 liver segments, between January 2000 and December 2015 were identified from a prospectively maintained database. RESULTS Major liver surgery was performed in 117 patients. Of these, 26 patients had undergone formal extended left or right hemihepatectomy. Ninety-day postoperative mortality was 8%. Major postoperative complications occurred in 27% of patients; these adverse events were more common in the extended hemihepatectomy group. Median disease-free survival was 11 months and median overall survival 44 months. CONCLUSION Major liver surgery, including formal extended hemihepatectomy, is associated with significant operative morbidity and mortality but can confer prolonged overall survival for patients with CRLM.
Collapse
Affiliation(s)
- Inge Ubink
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | - Maarten W Nijkamp
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Eelco F J Meijer
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Thomas T Vellinga
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | - I Quintus Molenaar
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | - Jeroen Hagendoorn
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.
| |
Collapse
|
4
|
Vellinga TT, den Uil S, Rinkes IHB, Marvin D, Ponsioen B, Alvarez-Varela A, Fatrai S, Scheele C, Zwijnenburg DA, Snippert H, Vermeulen L, Medema JP, Stockmann HB, Koster J, Fijneman RJA, de Rooij J, Kranenburg O. Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. Oncogene 2016; 35:5263-5271. [PMID: 26996663 DOI: 10.1038/onc.2016.60] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Revised: 01/11/2016] [Accepted: 01/19/2016] [Indexed: 12/16/2022]
Abstract
Gene expression-based classification systems have identified an aggressive colon cancer subtype with mesenchymal features, possibly reflecting epithelial-to-mesenchymal transition (EMT) of tumor cells. However, stromal fibroblasts contribute extensively to the mesenchymal phenotype of aggressive colon tumors, challenging the notion of tumor EMT. To separately study the neoplastic and stromal compartments of colon tumors, we have generated a stroma gene filter (SGF). Comparative analysis of stromahigh and stromalow tumors shows that the neoplastic cells in stromahigh tumors express specific EMT drivers (ZEB2, TWIST1, TWIST2) and that 98% of differentially expressed genes are strongly correlated with them. Analysis of differential gene expression between mesenchymal and epithelial cancer cell lines revealed that hepatocyte nuclear factor 4α (HNF4α), a transcriptional activator of intestinal (epithelial) differentiation, and its target genes are highly expressed in epithelial cancer cell lines. However, mesenchymal-type cancer cell lines expressed only part of the mesenchymal genes expressed by tumor-derived neoplastic cells, suggesting that external cues were lacking. We found that collagen-I dominates the extracellular matrix in aggressive colon cancer. Mimicking the tumor microenvironment by replacing laminin-rich Matrigel with collagen-I was sufficient to induce tumor-specific mesenchymal gene expression, suppression of HNF4α and its target genes, and collective tumor cell invasion of patient-derived colon tumor organoids. The data connect collagen-rich stroma to mesenchymal gene expression in neoplastic cells and to collective tumor cell invasion. Targeting the tumor-collagen interface may therefore be explored as a novel strategy in the treatment of aggressive colon cancer.
Collapse
Affiliation(s)
- T T Vellinga
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - S den Uil
- Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.,Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands
| | - I H B Rinkes
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - D Marvin
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - B Ponsioen
- Department Molecular Cancer Research, University Medical Center Utrecht, Utrecht, The Netherlands
| | - A Alvarez-Varela
- Department Molecular Cancer Research, University Medical Center Utrecht, Utrecht, The Netherlands
| | - S Fatrai
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - C Scheele
- Department Molecular Cancer Research, University Medical Center Utrecht, Utrecht, The Netherlands
| | - D A Zwijnenburg
- Department of Oncogenomics, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
| | - H Snippert
- Department Molecular Cancer Research, University Medical Center Utrecht, Utrecht, The Netherlands
| | - L Vermeulen
- Center of Experimental and Molecular Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
| | - J P Medema
- Center of Experimental and Molecular Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
| | - H B Stockmann
- Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands
| | - J Koster
- Center of Experimental and Molecular Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
| | - R J A Fijneman
- Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.,Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - J de Rooij
- Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands
| | - O Kranenburg
- Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
5
|
Vellinga TT, Borovski T, de Boer VCJ, Fatrai S, van Schelven S, Trumpi K, Verheem A, Snoeren N, Emmink BL, Koster J, Rinkes IHMB, Kranenburg O. SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer. Clin Cancer Res 2015; 21:2870-9. [PMID: 25779952 DOI: 10.1158/1078-0432.ccr-14-2290] [Citation(s) in RCA: 132] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 02/27/2015] [Indexed: 11/16/2022]
Abstract
PURPOSE Chemotherapy treatment of metastatic colon cancer ultimately fails due to development of drug resistance. Identification of chemotherapy-induced changes in tumor biology may provide insight into drug resistance mechanisms. EXPERIMENTAL DESIGN We studied gene expression differences between groups of liver metastases that were exposed to preoperative chemotherapy or not. Multiple patient-derived colonosphere cultures were used to assess how chemotherapy alters energy metabolism by measuring mitochondrial biomass, oxygen consumption, and lactate production. Genetically manipulated colonosphere-initiated tumors were used to assess how altered energy metabolism affects chemotherapy efficacy. RESULTS Gene ontology and pathway enrichment analysis revealed significant upregulation of genes involved in oxidative phosphorylation (OXPHOS) and mitochondrial biogenesis in metastases that were exposed to chemotherapy. This suggested chemotherapy induces a shift in tumor metabolism from glycolysis towards OXPHOS. Indeed, chemotreatment of patient-derived colonosphere cultures resulted in an increase of mitochondrial biomass, increased expression of respiratory chain enzymes, and higher rates of oxygen consumption. This was mediated by the histone deacetylase sirtuin-1 (SIRT1) and its substrate, the transcriptional coactivator PGC1α. Knockdown of SIRT1 or PGC1α prevented chemotherapy-induced OXPHOS and significantly sensitized patient-derived colonospheres as well as tumor xenografts to chemotherapy. CONCLUSIONS Chemotherapy of colorectal tumors induces a SIRT1/PGC1α-dependent increase in OXPHOS that promotes tumor survival during treatment. This phenomenon is also observed in chemotherapy-exposed resected liver metastases, strongly suggesting that chemotherapy induces long-lasting changes in tumor metabolism that potentially interfere with drug efficacy. In conclusion, we propose a novel mechanism of chemotherapy resistance that may be clinically relevant and therapeutically exploitable.
Collapse
Affiliation(s)
- Thomas T Vellinga
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Tijana Borovski
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Vincent C J de Boer
- Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Szabolcs Fatrai
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Susanne van Schelven
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Kari Trumpi
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Andre Verheem
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Nikol Snoeren
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Benjamin L Emmink
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Jan Koster
- Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | | | - Onno Kranenburg
- Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
| |
Collapse
|
6
|
Trumpi K, Egan DA, Vellinga TT, Borel Rinkes IHM, Kranenburg O. Paired image- and FACS-based toxicity assays for high content screening of spheroid-type tumor cell cultures. FEBS Open Bio 2015; 5:85-90. [PMID: 25685667 PMCID: PMC4325131 DOI: 10.1016/j.fob.2015.01.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2014] [Revised: 12/17/2014] [Accepted: 01/15/2015] [Indexed: 01/09/2023] Open
Abstract
Design of a high throughput toxicity assay for spheroid-type tumor cell cultures. Cell viability, rather than a proxy thereof, is measured. Cell viability is measured on a per-cell, rather than per-well, basis. The method can be implemented on standard automated microscopes. It provides a low-cost approach for accurate and reproducible toxicity screens.
Novel spheroid-type tumor cell cultures directly isolated from patients’ tumors preserve tumor characteristics better than traditionally grown cell lines. However, such cultures are not generally used for high-throughput toxicity drug screens. In addition, the assays that are commonly used to assess drug-induced toxicity in such screens usually measure a proxy for cell viability such as mitochondrial activity or ATP-content per culture well, rather than actual cell death. This generates considerable assay-dependent differences in the measured toxicity values. To address this problem we developed a robust method that documents drug-induced toxicity on a per-cell, rather than on a per-well basis. The method involves automated drug dispensing followed by paired image- and FACS-based analysis of cell death and cell cycle changes. We show that the two methods generate toxicity data in 96-well format which are highly concordant. By contrast, the concordance of these methods with frequently used well-based assays was generally poor. The reported method can be implemented on standard automated microscopes and provides a low-cost approach for accurate and reproducible high-throughput toxicity screens in spheroid type cell cultures. Furthermore, the high versatility of both the imaging and FACS platforms allows straightforward adaptation of the high-throughput experimental setup to include fluorescence-based measurement of additional cell biological parameters.
Collapse
Affiliation(s)
- Kari Trumpi
- Department of Surgery,, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands
| | - David A Egan
- Cell Screening Core, Department of Cell Biology, Centre for Molecular Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands
| | - Thomas T Vellinga
- Department of Surgery,, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands
| | - Inne H M Borel Rinkes
- Department of Surgery,, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands
| | - Onno Kranenburg
- Department of Surgery,, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands
| |
Collapse
|
7
|
Vellinga TT, Boer VCD, Borovski T, Trumpi K, Fatrai S, Kranenburg O, Rinkes IHB, Hagendoorn J. Abstract 3351: Survival of colorectal cancer cells following chemotherapy relies on a SIRT1-dependent increase in oxidative phosphorylation. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-3351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Altered energy metabolism is one of the hallmarks of cancer. Tumor cells reprogram their energy metabolism to meet the demands of uncontrolled cell division. During tumorigenesis the vast majority of cancer cells become highly glycolytic (Warburg effect) accompanied by a decrease in oxidative metabolism. Chemotherapy is likely to affect the energy metabolism of tumor cells, but how specific drugs affect specific metabolic pathways is only beginning to be addressed.
Methods: the effects of cytotoxic agents on energy metabolism were assessed by flow cytometric uptake of Mitotracker®, the ratio of mitochondrial and nuclear DNA on qRT-PCR, western blotting for protein levels of the different complexes of the respiratory chain and oxygen consumption rate by the Seahorse Extracellular Flux Analyzer. Cell death was analyzed by flow cytometric uptake of Propidium Iodide, Nicoletti assay and protein levels of caspases 3 and 8.
Results: Gene expression analysis was performed on 119 resected liver metastases of colorectal tumors. Of all clinical variables tested, neoadjuvant chemotherapy was most prominently associated with changes in gene expression. Gene ontology and pathway analysis tools revealed that many of the chemotherapy-associated genes were involved in the regulation of oxidative phosphorylation (OxPhos). To test whether chemotherapy affects OxPhos patient derived colorectal spheroids were treated with the standard cytotoxic agents oxaliplatin and 5-fluorouracil. Chemotherapy strongly increases mitochondrial load, oxygen consumption rate and mitochondrial ATP synthesis.
In line with these results chemo-treated tumor cells displayed a higher ratio of mitochondrial-to-nuclear DNA and expression of respiratory complex components was strongly increased following chemotherapy. Chemotherapy strongly induced expression of the histone deacetylase SIRT1, which has been implicated in mitochondrial biogenesis. Inhibition (by either nicotinamide, EX-527, Tenovin-6) or knockdown of SIRT1 prevented the chemotherapy-induced increase in oxidative phosphorylation. Moreover, SIRT1 knockdown greatly reduced tumor cell survival and clonogenic capacity following removal of chemotherapy.
Conclusion: Chemotherapy induces an increase in oxidative phosphorylation via SIRT1 and this is required for tumor cell survival following drug removal. Since DNA repair requires ATP, mitochondrial biogenesis may be part of the tumor cell response to DNA-damaging agents. Post-chemotherapy targeting of SIRT1 (or OxPhos enzymes) may be an interesting novel approach to increase chemotherapy efficacy.
Citation Format: Thomas T. Vellinga, Vincent C. de Boer, Tijana Borovski, Kari Trumpi, Szabolcs Fatrai, Onno Kranenburg, Inne H.M. Borel Rinkes, Jeroen Hagendoorn. Survival of colorectal cancer cells following chemotherapy relies on a SIRT1-dependent increase in oxidative phosphorylation. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3351. doi:10.1158/1538-7445.AM2014-3351
Collapse
Affiliation(s)
| | | | | | - Kari Trumpi
- 1University Medical Centre Utrecht, Utrecht, Netherlands
| | | | | | | | | |
Collapse
|
8
|
Einarsson JI, Suzuki Y, Vellinga TT, Jonsdottir GM, Magnusson MK, Maurer R, Yoshida H, Walsh B. Prospective Evaluation of Quality of Life in Total versus Supracervical Laparoscopic Hysterectomy. J Minim Invasive Gynecol 2011; 18:617-21. [DOI: 10.1016/j.jmig.2011.06.003] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2011] [Revised: 05/25/2011] [Accepted: 06/02/2011] [Indexed: 11/17/2022]
|
9
|
Abstract
OBJECTIVE To evaluate the safety and efficacy of using bidirectional barbed suture in laparoscopic myomectomy (LM) and total laparoscopic hysterectomy (TLH). METHODS This was a case series of clinical outcomes following 172 consecutive LM and TLH cases over a 1-year period conducted at a university teaching hospital. It included 172 women (ages 17 to 81), requiring a myomectomy or hysterectomy for symptomatic uterine fibroids, pelvic pain, or abnormal uterine bleeding; 117 women underwent TLH and 55 women underwent LM. Patients were contacted over the phone 6 months after surgery to inquire about number of days of postoperative vaginal bleeding, visits to the hospital due to bleeding, dyspareunia, and other potential complications. RESULTS For TLH, the average duration of surgery was 109 minutes, average uterine weight was 256 grams (range, 18 to 1242), and average blood loss was 71 mL. In LM, average duration of surgery was 125 minutes, average weight of fibroids was 252 g, average number of fibroids removed was 4.0, and average blood loss was 159 mL. Seven percent of patients and 8% of their partners had persistent dyspareunia after surgery. There were no conversions to laparotomy. CONCLUSIONS The use of bidirectional barbed suture appears to be safe for closing the vaginal cuff in a TLH and for closing the hysterotomy site during a laparoscopic myomectomy.
Collapse
Affiliation(s)
- Jon I Einarsson
- Brigham and Women's Hospital, 75 Francis St, ASB 1-3, Boston, MA 02118, USA.
| | | | | | | | | | | |
Collapse
|
10
|
Suzuki Y, Vellinga TT, Istre O, Einarsson JI. Small Bowel Obstruction Associated With Use of a Gelatin-Thrombin Matrix Sealant (FloSeal) after Laparoscopic Gynecologic Surgery. J Minim Invasive Gynecol 2010; 17:641-5. [DOI: 10.1016/j.jmig.2010.03.024] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2009] [Revised: 03/15/2010] [Accepted: 03/17/2010] [Indexed: 11/25/2022]
|
11
|
Vellinga TT, Suzuki Y, Istre O, Einarsson JI. Anatomic considerations in gynecologic surgery. Rev Obstet Gynecol 2009; 2:137-138. [PMID: 19826570 PMCID: PMC2760906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Affiliation(s)
- Thomas T Vellinga
- Department of Obstetrics and Gynecology, Division of Minimally Invasive Gynecologic Surgery, Brigham and Women's Hospital Boston, MA
| | | | | | | |
Collapse
|
12
|
Vellinga TT, De Alwis S, Suzuki Y, Einarsson JI. Laparoscopic entry: the modified alwis method and more. Rev Obstet Gynecol 2009; 2:193-198. [PMID: 19826577 PMCID: PMC2760894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Despite the rapid advances in laparoscopic surgery in the past 2 decades, the initial entry still accounts for approximately 40% to 50% of laparoscopic complications and should be considered the most dangerous step of a laparoscopic procedure. In this review, the authors share a technique for initial umbilical entry, and provide alternative entry sites in cases where umbilical entry is contraindicated.
Collapse
|